Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
about
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@en
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@nl
type
label
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@en
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@nl
prefLabel
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@en
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@nl
P2093
P2860
P356
P1433
P1476
Docetaxel, bevacizumab, and an ...... l therapy for prostate cancer.
@en
P2093
Arif Hussain
Glenn J Bubley
Jonathan E Rosenberg
Julia H Hayes
Kathryn P Gray
Rana R McKay
P2860
P304
P356
10.1002/CNCR.29398
P407
P577
2015-04-22T00:00:00Z